The quest to overcome resistance to EGFR-targeted therapies in cancer. - Wikidata - awgldk - TriplyDB

The quest to overcome resistance to EGFR-targeted therapies in cancer.

The quest to overcome resistance to EGFR-targeted therapies in cancer.

http://www.wikidata.org/entity/Q33725976

about

Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer Pancreatic Cancer from Molecular Pathways to Treatment Opinion The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer Mechanisms underlying skin disorders induced by EGFR inhibitors MLK3 Signaling in Cancer Invasion Pancreatic cancer from bench to bedside: molecular pathways and treatment options Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers Somatic DNA mutation analysis in targeted therapy of solid tumours Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging Viro-immune therapy: A new strategy for treatment of pancreatic cancer The influence of subclonal resistance mutations on targeted cancer therapy Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer Heterotrimeric G proteins as emerging targets for network based therapy in cancer: End of a long futile campaign striking heads of a Hydra Ten things you should know about protein kinases: IUPHAR Review 14 Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer Epidermal growth factor, from gene organization to bedside Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer Enhancing the efficacy of cytotoxic agents for cancer therapy using photochemical internalisation Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.HER2 activating mutations are targets for colorectal cancer treatment Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win?FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine Familial Lung Cancer: A Brief History from the Earliest Work to the Most Recent Studies Targeted noninvasive imaging of EGFR-expressing orthotopic pancreatic cancer using multispectral optoacoustic tomography.Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance.Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions.EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC).Selective Killing Effects of Cold Atmospheric Pressure Plasma with NO Induced Dysfunction of Epidermal Growth Factor Receptor in Oral Squamous Cell Carcinoma MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.Molecular pathways and therapeutic targets in lung cancer

P2860

Q24564024-47987FA3-61F1-4ABA-80F8-DDA1A9A033B7 Q26741998-17F9109D-D52D-45C9-B223-169D620F9ACD Q26743482-8069E883-4839-4FB8-906B-CE52A0DDBD4D Q26744721-CB1980EB-5673-4057-8F39-66087B4CD09C Q26745689-6C938F5A-E163-4102-8DF6-75E5AA699247 Q26746892-2AA957B8-DC51-4256-A372-5EFCD1486659 Q26747524-B0696DB4-3036-4508-831F-C51F89EE2A07 Q26751473-CA60B0E8-400A-4190-A8EC-D05C3895E7E7 Q26770324-E2829164-EA72-41C0-A297-4DF94C57A51F Q26774478-F390CB4E-65EF-4AA7-8D23-28921918B93C Q26774641-D971F202-A48A-4443-B0BC-E61C3E136031 Q26781693-A9546A29-626E-4313-A74E-CE842CDC6F61 Q26784298-C4AE5F5F-836F-4440-ADAF-2559AB28954A Q26801694-5B6AB7B7-72AB-4062-BB76-DF005813DEF4 Q26849417-4C807680-2826-4BDD-B111-E9B9F3C4C83E Q26851421-185A09A8-FD90-4A5A-8F75-F5095569DF64 Q26865616-64A1E38B-5AFD-4738-A75C-9621668261A1 Q26865779-6DD3E96F-C8E9-4638-BBDA-90275953AF0A Q26998547-964DC2D8-A4F5-409C-9A35-9ABEFD03E2DD Q27004161-1B9787FF-36FF-43B9-8B65-3FF45692F566 Q27015224-1B4458BF-5988-4A88-AB8D-02CE7BBD03B4 Q27345462-F3A3F78C-0067-4175-A376-86B5AADCEAD3 Q27853193-1A42CFC4-C162-43F9-8358-DC07ED977E32 Q27853214-F99F4843-308B-499E-B7EE-D3DE75817CAB Q28077340-5BDE76A0-D480-4441-BB34-33FC18996A17 Q28077347-003203A8-DFE6-4CD7-900B-047D00D362E5 Q28080730-204A1F63-01FB-4F18-B77E-B4122F07B42B Q28086993-1029E9CD-B299-4FCF-B2C8-3F63D7F6DA3D Q28553627-B282AFF1-F6F1-4FFB-9A6D-BBE99EE63EEC Q29248944-7E02F8E7-CCB2-4AB7-9D90-148D7E6DC174 Q30399746-8BA107F0-9945-473D-97D5-CBC10353F988 Q30729579-F119CE39-1C92-4FF7-B200-DE93D3E59BE6 Q30850656-FA80DAA4-21D2-4E2C-9245-258D248B1A90 Q31053925-89D44966-6E50-4CEF-B5D9-1D318E758AB7 Q33276007-02A7386D-9AE9-42EF-A085-BA8029EC4B37 Q33437650-E9FC79DB-A42C-42A3-99D7-E008423962B6 Q33467304-846E76B7-31D1-44F6-9071-5DE1930B26AA Q33590325-5368710A-E962-498D-B032-9635FFAAF6EA Q33604480-629C30CD-BF12-4071-ACBF-D1F2C3AB9FE2 Q33688872-E4DEF309-03E1-4A96-B8B9-CA833D2DF764

P2860

The quest to overcome resistance to EGFR-targeted therapies in cancer.

http://www.wikidata.org/entity/Q33725976

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

The quest to overcome resistance to EGFR-targeted therapies in cancer.

@ast

The quest to overcome resistance to EGFR-targeted therapies in cancer.

@en

type

label

The quest to overcome resistance to EGFR-targeted therapies in cancer.

@ast

The quest to overcome resistance to EGFR-targeted therapies in cancer.

@en

prefLabel

The quest to overcome resistance to EGFR-targeted therapies in cancer.

@ast

The quest to overcome resistance to EGFR-targeted therapies in cancer.

@en

P1433

Q33725976-98A6D104-FE62-4E89-87E2-E1011C8B8FFD

P1476

Q33725976-877C064D-A3BF-4912-91D1-3D30146716C7

P2093

Q33725976-D2AAFC80-E822-4F0B-A5BF-DDCD9E693961

P2860

Q33725976-01293D1C-3F47-4A23-BEDB-C1823FC5886C

Q33725976-014A8D71-CD24-4439-9D9E-ED3B1CF80C90

Q33725976-01EFBAB3-DC8D-4790-BF17-D8D589E03789

Q33725976-02E5792B-F381-4253-8C04-9952BF3ACB3F

Q33725976-04D8E2D9-B50D-47DA-9E6A-B6FA5C023FE4

Q33725976-08531B40-EDF8-4E0C-AD02-1B6FF0F2DA6D

Q33725976-09D5BC3F-7620-4CE7-8324-87BD12DD3F08

Q33725976-09E99A61-92F2-4884-96CB-0A2AB02E2A52

Q33725976-0E0B3F3B-ECF3-4D10-8E94-4DE6804C8EFF

Q33725976-155F6E6F-C4A3-49CD-AF71-FC9976E44409

P2888

Q33725976-9725C979-5429-413B-A94A-83F4613E5504

P304

Q33725976-5D50A088-BF5C-4E6D-B981-8BF4716C9DD2

P31

Q33725976-D213CEA3-B50E-414C-98D1-2BCFE52DFE41

P356

Q33725976-1CB32EBC-341E-4C21-B755-E94DEB5D7D45

P407

Q33725976-B9D6ECBD-7DA3-4B36-9609-B5E0C7578B73

P433

Q33725976-C14CCBD7-FAFA-43C3-8D46-37A388C6E069

P478

Q33725976-4BA59DD8-3F05-443C-9349-0C2D42B32548

P50

Q33725976-882F58BD-5940-4AE6-9357-F7DF6EE89DED

P577

Q33725976-2AFDFE1B-7AA2-427F-8AEA-2EA5A1A5F277

P5875

Q33725976-412C4A27-0666-42B0-8750-F76BE56D323C

P6179

Q33725976-E5B9FF25-06CC-4125-AE33-A672F764F596

P698

Q33725976-1D36DC90-085D-4BF8-AA6C-D938EE256D54

P932

Q33725976-AF1C96BE-F34A-48D1-B411-AC89F3541123

P356

P1433

Nature Medicine

P1476

The quest to overcome resistance to EGFR-targeted therapies in cancer.

@en

P2093

Curtis R Chong

http://www.w3.org/2001/XMLSchema#string

P2860

Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling

NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma

Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

P2888

P304

1389-1400

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.3388

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258348937

http://www.w3.org/2001/XMLSchema#string

P6179

1044316748

http://www.w3.org/2001/XMLSchema#string

P698

24202392

http://www.w3.org/2001/XMLSchema#string

P932

4049336

http://www.w3.org/2001/XMLSchema#string